A Listeria monocytogenes glcV mutation precludes the binding of certain listerial phages and produces a profound attenuation characterized by the absence of detectable mutants in the livers and spleens of orally inoculated mice. In vitro, we found that the mutant formed plaques on mouse enterocyte monolayers as efficiently as the parent but the plaques formed were smaller. Intracellular growth rate determinations and examination of infected enterocytes by light and fluorescence microscopy established that the mutant was impaired not in intracellular growth rate but in cell-to-cell spreading. Because this property is shared by other immunogenic mutants (e.g., actA mutants), our glcV mutant was tested for vaccine efficacy. Oral immunization with the mutant and subsequent oral challenge (22 days postvaccination) with the parent revealed a ca. 10,000-fold increase in protection afforded by the mutant compared to sham-vaccinated controls. The glcV mutant did not stimulate innate immunity under the dose and route employed for vaccination, and an infectivity index time course experiment revealed pronounced mutant persistence in Peyer's patches. The immunogenicity of the glcV mutant compared to an isogenic actA mutant reference strain was next tested in an experiment with a challenge given 52 days postvaccination. Both mutant strains showed scant vital organ infectivity and high levels of protection similar to those seen using the glcV mutant in the 22-day postvaccination challenge. Our results indicate that oral administration of a profoundly attenuated listerial mutant can safely elicit solid protective immunity.
Listeria monocytogenes (6) is a Gram-positive, food-borne pathogen that can cause systemic disease in immunocompromised and pregnant individuals. In immunocompetent hosts, the infection is effectively cleared, and the T-cell-mediated immunity conferred is robust and long-lived (20) . The ability to engender strong T-cell-mediated immunity is directly related to the microorganism's ability to survive and multiply within cells of the reticuloendothelial system; listerial mutants that have lost the ability to escape the initial macrophage phagocytic vacuole (e.g., listeriolysin O [LLO] mutants) are killed effectively and do not immunize mice against a secondary listerial challenge (3) . Listerial immunogenic properties can be exploited by genetically engineering the microorganisms to produce a variety of antigens that are presented during cytosolic growth (25) .
Substantial efforts have been applied to the genetic construction of listerial vaccine strains (platforms) that are attenuated but can nevertheless display heterologous antigens that induce an immune response characteristic of a normal listerial infection (1, 11, 16) . These efforts have been largely successful (4, 25, 28) . However, our present understanding of the immunostimulatory steps in listeriosis is incomplete. This is especially true for the oral inoculation route, for which few, but relatively encouraging, studies have been preformed (21, 27) . One consequence of the sparse use of the oral infection route is that the minimal level of host stimulation (i.e., how severe an infection has to be to engender protective, long-lasting immunity) remains unclear.
We recently described a phage-resistant listerial strain that when orally administered to mice was dramatically less pathogenic than the parental strain (26) . No evidence of the characteristic spreading from the intestinal lumen to the liver and spleen was observed (31) . The lesion mapped to a gene whose trans-acting product (a predicted glycosyltransferase) precluded phage binding. Herein, we describe the mutant's distinctive interactions with cultured mouse enterocytes that suggested its safety and possible utility as a live vaccine strain. Subsequent in vivo protection studies using oral vaccination and oral challenge revealed a strikingly high level of protection.
MATERIALS AND METHODS
Bacterial strains, cell culture, and media. Parental L. monocytogenes strain F6214-1 is a spontaneous streptomycin-resistant derivative of a serotype 4nonb strain, F6214 (12) . L. monocytogenes strain PAS394 is isogenic to F6214-1, except for an insertion of Tn917 in the glcV gene (glcV::Tn917) that is attenuating and renders the strain resistant to listerial bacteriophage P35h4 (31) . L. monocytogenes strain PAS733 is isogenic to F6214-1, except for an insertion of an erythromycin cassette in the actA gene. Unless otherwise noted, bacterial strains were propagated at temperatures ranging from 31 o to 37°C in brain heart infusion (BHI) broth or in BHI broth supplemented with 1.2% agar (31) . Broth-grown bacteria destined for mouse inoculation were prepared as described by Hamrick et al. (12) . Listerial strains destined for testing enterocyte binding and plaqueforming ability on monolayers were grown as described by Spears et al. (31) . When necessary, antibiotics were incorporated into the media at the following concentrations: chloramphenicol, 10 g/ml; streptomycin, 50 g/ml; nalidixic acid, 40 g/ml; erythromycin, 1 g/ml; lincomycin, 25 g/ml.
Cell culture methods. Undifferentiated cultured mouse enterocytes, MODE K (33), were propagated as monolayers as previously described (12) . Bacteria, prepared as described above, in 1.0 ml of Dulbecco's modified Eagle medium (DMEM) and 5% fetal bovine serum (FBS) were added to MODE K monolayers in 6-well tissue culture plates for 10 min. Bacterial numbers bound to MODE K cells and plaque numbers were determined as previously described (12) . Plaque formation was assessed at both 48 and 72 h postbinding in parallel sets of wells after monolayers were fixed with 100% methanol and enterocytes were stained with HEMA 3, Solution II (Protocol; Fisher Scientific). Plaques were enumerated, and plaque sizes (area in pixels) were measured using the AlphaImager 3300 v2.03 Spot Denso analysis tool (Alpha Innotech Corp.).
Construction of an actA⍀erm insertion mutation. An erythromycin resistance cassette (erm) from Tn917 was inserted into the F6214-1 actA allele with ca. 60% of its central coding capacity deleted. The deletion mutation was constructed in vitro on temperature-sensitive replication plasmid pKSV7 (30) using PCR (for the primers used, see Table S1 in the supplemental material) and In-Fusion cloning technology (Clontech) (35) as directed by the manufacturer, followed by the addition of the erm cassette, resulting in plasmid pPAS710 (see Fig. S1A and B in the supplemental material). All plasmid maintenance and transfer procedures were as previously described (31) . The actA⍀erm fusion on pPAS710 was introduced into the F6214-1 chromosome by allelic exchange (see Fig. S2 in the supplemental material). This resulted in the replacement of the parental actA gene with actA⍀erm and the creation of strain PAS733. The exchange was confirmed by PCR [see Table S1 in the supplemental material]). Strain PAS733 was demonstrably deficient in the ca. 70-kDa actA product (ActA) compared to both the parental strain (F6214-1) and our glcV mutant strain (PAS394) by Western blot analysis (see Fig. S3 in the supplemental material). To address concerns that an insertion in actA would preclude the expression of the transcriptionally downstream plcB gene (thus curtailing normal phospholipase C activity), we took the precaution of assaying lecithinase activity (32) at 37°C and 42°C. Inspection revealed no noticeable difference in lecithinase activity between mutant and parent (data not shown).
Production of rabbit F6214-1 antiserum. Antiserum was generated by a modification of the procedure described by Havell et al. (15) . Briefly, young adult female New Zealand White rabbits (2.2 to 2.4 kg) were bled several times prior to the initiation of immunization for preimmune sera. The initial immunization consisted of an equal volume (1.0 ml) of UV-inactivated L. monocytogenes F6214-1(10 8 CFU equivalents) emulsified in 1 ml of Freund's complete adjuvant. The emulsion was inoculated subcutaneously at multiple sites. At three successive 2-week intervals, the procedure was repeated using Freund's incomplete adjuvant. Immediately prior to each injection, rabbits where bled and the sera were collected and inactivated at 56°C for 30 min and then stored at Ϫ20°C prior to titration for antilisterial antibodies.
Light and fluorescence microscopy. MODE K monolayers in 4-chamber culture slides (Nunc Lab-Tek) were employed to examine listerial infectivity using light and fluorescence microscopy. Chambers were seeded with 0.2 ϫ 10 5 to 2.0 ϫ 10 5 MODE K cells in 0.8 ml of DMEM at least 48 h prior to infection. MODE K enterocytes were infected with 2 ϫ 10 8 listerial CFU per chamber for 30 min, unbound listeriae were removed, enterocytes washed with Hanks balanced salt solution (HBSS), and gentamicin-containing medium was added to the culture chambers. After 48 h, the medium was removed. MODEK monolayers destined for light microscopy were fixed with 100% methanol and stained with Protocol. Monolayers destined for fluorescence microscopy were washed with phosphate-buffered saline (PBS) and then fixed in PBS containing 4% paraformaldehyde for 30 min at 37°C. Cells were washed with PBS and then treated with PBS containing 0.2% Triton X-100 for 10 min at room temperature. Monolayers were further washed in PBS and then incubated in PBS containing 5% bovine serum albumin (BSA) for 30 min at room temperature prior to the addition of primary rabbit polyclonal anti-Listeria antisera (described above) at 1:150 in PBS containing 1% BSA for 1 h at room temperature. Following incubation, monolayers were washed with PBS and then a secondary mouse anti-rabbit-fluorescein isothiocyanate (FITC; Molecular Probes) antibody was added (after dilution [1:250] in PBS containing 1% BSA) for 1 h at room temperature. Following this incubation, monolayers were washed with PBS, Alexa Fluor phalloidin 594 (Molecular Probes) was added, and the chambers were incubated for 30 min at room temperature. Following phalloidin staining, monolayers were washed with PBS, dried, coverslipped with VectaShield hard set (Vector Laboratories), and viewed on an Infinity3 fluorescence microscope using Lumenera Infinity3 analysis v4.6 software. Images were merged using Adobe Photoshop CS4.
In vitro IFN induction and assay. L. monocytogenes strains F6214-1 and PAS394 were used to induce alpha/beta interferon (IFN-␣/␤) synthesis in MODE K enterocyte monolayers essentially as previously described (13) . Briefly, MODE K cells cultured as described above were inoculated with ca. 2.5 ϫ 10 8 CFU of listeriae in 1.0 ml antibiotic-free medium. After 30 min, unbound listeriae were aspirated, monolayers were washed twice with HBSS, and medium containing gentamicin (5 g/ml) was added to the culture wells. Medium was withdrawn from replicate triplicate culture wells at 24, 48, and 72 h; bacteria and debris were removed by centrifugation; and the supernatant was filter sterilized and stored at Ϫ20°C until assayed. Parallel triplicate wells were lysed with 0.1% Triton X-100, and lysates were diluted and plated to determine CFU counts as previously described (12) . The supernatants were assayed for antiviral activity (units/ml) as previously reported (13) .
Vaccination and challenge. For the 22-day challenge, two groups of 6-to 8-week-old female A/J mice (Jackson Laboratories) were either sham inoculated with PBS (8 mice) or inoculated with PAS394 (16 mice). Oral PAS394 inoculations were carried out with a single dose (ca. 2 ϫ 10 7 CFU) delivered in 20 l of PBS. Sham vaccinees (unvaccinated mice) received 20 l of PBS. Prior to administration of the challenge strain, pairs of vaccinated mice were sacrificed on days 3, 10, and 15 postvaccination to monitor the presence of the vaccine strain (genetically marked with erythromycin and lincomycin resistance) in their colon contents, livers, and spleens. The challenge parent strain (F6214-1) was administered (ca. 1.5 ϫ 10 8 CFU) 22 days postvaccination to 8 sham-vaccinated mice (controls) and to 10 vaccinated mice. Four sham-vaccinated and four vaccinated mice were sacrificed 3 and 5 days postchallenge. The livers, spleens, and colon contents were removed and homogenized for plating on BHI agar containing the antibiotics streptomycin and nalidixic acid. Two additional mice in the vaccinated group were monitored for an additional 13 days postchallenge for signs of disease. A second vaccination and 52-day challenge experiment employed 2 different vaccine strains (PAS394 or PAS733), 16 mice in each vaccination group, and 8 sham-vaccinated mice. The 52-day challenge experiment was performed as described above, except that postvaccination monitoring was done 3, 5, and 10 days postvaccination. Two groups of 4 mice each were inoculated parenterally. Each group received either the parental or glcV mutant stain (ca. 4 ϫ 10 4 CFU via tail vein injection in 0.2 ml PBS). Two mice from each group were sacrificed 72 and 96 h postinoculation, and CFU counts in the livers and spleens were determined.
Innate immune response to vaccination. To assess IFN-␥-mediated priming for augmented cytokine production, a parameter of innate immunity (13, 14) , six groups of 4 female A/J mice (8 to 10 weeks old) were inoculated orally with 2 ϫ 10 7 CFU of either the parental strain (F6214-1) or the phage-resistant mutant (PAS394) in PBS (20 l). An identical group was sham inoculated with PBS. Three days postinoculation, paired groups of mice were injected intravenously either with Salmonella enterica serovar Enteritidis lipopolysaccharide (LPS; 5 g in 0.2 ml of PBS) or with PBS. A group of LPS-injected mice not having received listeriae (sham vaccinated) served as a control. Two hours later, blood was collected and the serum was assayed for tumor necrosis factor alpha (TNF) and IFN-␣/␤. The serum TNF and IFN-␣/␤ activities were quantified and adjusted to international units of activity (U/ml) as previously reported (13, 14) after correction for baseline cytokine levels in control groups of mice that received PBS rather than LPS stimulation.
Gut-associated lymphoid tissue (GALT) infection indices. Four groups of 2 female A/J mice were orally inoculated with a ca. 2:1 mixture of the parental (F6214-1) and glcV mutant (PAS394) strains (ca. 2 ϫ 10 8 total microorganisms) in 20 l PBS. At selected times postinoculation, 2 mice were sacrificed and CFU counts in selected organs were determined. Livers, spleens, mesenteric lymph nodes (MLN; 5 to 7 nodes per mouse), Peyer's patches (PP) (8 to 10 PP per mouse), and colon contents (2 fecal pellets per mouse) were harvested. Livers, spleens, and colon contents were homogenized and treated as previously described for determination of CFU counts (12) . PP were removed from the small intestines of each mouse, blotted on sterile filter paper to remove intestinal contents on the luminal surface, and washed in 5.0 ml Eagle's minimal essential medium supplemented with 5% FBS and 5 g/ml gentamicin. The patches were then collected by centrifugation (800 ϫ g for 2 min) and washed once in PBS prior to homogenization in 1.0 ml PBS. MLN were homogenized in 1.0 ml PBS. After removal of aliquots for serial dilution, the remainder of the PP and MLN homogenates were concentrated by centrifugation (13,000 ϫ g, 2 min) and the remainder was resuspended in a small volume and plated. Mutant and parental strains were determined following replica printing of recovered listeriae on selective agar plates as previously described (12) .
Statistical methods. Standard deviations of means were calculated with the aid of the Microsoft Excel STDEV function. Standard errors were calculated by dividing the standard deviation by the square root of the number of samples. With the exception of animal experiments, significant differences between means were determined using Student's t test with the aid of the Microsoft Excel TTEST function. For the animal experiments, significant differences between population means were distinguished using the Mann-Whitney test with the aid of GraphPad Prism. The error probability threshold was a P value of Ͻ0.05.
RESULTS
Plaque formation on MODE K enterocytes. Prior results (31) indicate that the efficiencies of binding of the parental strain (F6214-1) and the phage-resistant mutant (PAS394) to enterocyte monolayers are indistinguishable but that plaqueforming efficiency (number of plaques formed/number of listeriae bound) is reduced when assessed after 48 h of incubation. The reduced plaque-forming efficiency could have been due to one or a combination of the following individual possibilities: (i) a low probability that an enterocyte-bound mutant would replicate in the initially infected cell, (ii) a reduced intracellular growth rate, and (iii) an impaired ability to spread to adjacent cells. Observations made at 72 h postinoculation in the present study revealed that mutant plaques, while expanding in size at a relatively low rate (Fig. 1A) , were formed with an efficiency that was indistinguishable from that of the parent (Fig. 1B) . This finding indicated that possibility i could be ruled out but left open possibilities ii and iii. Accordingly, we next examined possibility ii by determining the intracellular growth rates of the parent and mutant.
Intracellular growth in MODE K enterocytes. Intracellular growth curves were generated with measurements taken at ca. 2-h intervals for the first several generations (up to 8 h) and subsequently at 24, 48, and 72 h. There was no distinguishable difference between mutant and parental intracellular growth rates over the first 8 h (Fig. 2A) . However, at 24 and 48 h, significant differences in population size were noted before the numbers of both mutant and parent strain bacteria declined at 72 h (Fig. 2B) . Ostensibly, the decline at 72 h was due to the effects of prolonged incubation in gentamicin-containing medium.
The unimpeded initial growth of the mutant suggested that it was capable of escaping the uptake vacuole and gaining access to the cytosol since an otherwise isogenic hly mutant (LLO deficient) failed to show any evidence of intracellular growth (data not shown). It further indicated that the ability of the mutant to commence replication in the cytoplasm was not impaired and thus this feature could not be responsible for the small-plaque phenotype. Consequently, we concentrated on possibility iii-impairment of cell-to-cell spreading. If the glcV mutant had a reduced ability to spread from cell to cell, then we would predict that it would reach a higher density in the cytosol of infected cells than that of the parent when examined microscopically. Intracellular listerial density and distribution. In order to observe early intracellular events, the leading edges of listerial plaques (formed on coverslips) were examined following Protocol staining ca. 48 h postinoculation. Using light microscopy, we found that the mutant-infected MODE K cells showed a strikingly denser intracellular colonization level than the parent (Fig. 3) . This finding was consistent with an impaired ability to spread cell to cell. Also supportive was the observation that IFN-␣/␤ production was curtailed in mutant-infected enterocyte monolayers (Table 1 ). The mutant induced ca. 100-fold less IFN-␣/␤ antiviral activity than the parent at 48 h postinoculation, even though its numbers at that time were just ca.
10-fold less. This disproportionate drop was consistent with fewer but more densely infected enterocytes.
To better appreciate differences between the parent and mutant strains in terms of bacterial spreading from an infectious focus, we employed fluorescence microscopy and differential staining to highlight the listerial distribution in a cell monolayer and allow a larger field of view to be employed. Chamber slides containing infected MODE K enterocytes were stained with phalloidin and rabbit antilisterial polyclonal antibody to determine the location of the bacteria during plaque formation (Fig. 4A) . Differential staining clearly showed the mutant confined to a tight ring of infected cells immediately surrounding a plaque containing listerial antigenic material. Fourfold higher magnification (Fig. 4B) revealed this material to be largely mutant debris. In contrast, the parental strain was distributed widely, with few cells and little debris in the center of its large and diffuse-edged plaques. Phalloidin staining of mutant and parental individuals revealed similar levels of actin deposition (Fig. 4B, inset ). An F6214-1 actA mutant (PAS733) that was constructed as a control strain for the vaccination experiments showed a plaque-forming characteristic similar to that of the glcV mutant (see Fig. S4 in the supplemental material) and an absence of phalloidin staining (data not shown). The glcV mutant's behavior, as revealed by light and fluorescence microscopy, was consistent with its robust ability to grow intracellularly but limited ability to spread between cells in the protected fashion characteristic of the parent. These properties, combined with its undetectability in vital organs (31) , suggested that the strain might be an effective vaccine candidate.
Vaccination and challenge. Oral vaccination with the mutant strain (PAS394) was carried out with female A/J mice as described in Materials and Methods. Selected prechallenge vaccinees were sacrificed at 3, 10, and 15 days postinoculation (two mice at each time point), and liver, spleen, and colon contents were plated to detect the genetically marked vaccine strain. The vaccine strain was recovered in the colon contents of all mice tested at 3 days postinoculation. However, it was undetectable in all other samples from any mouse sampled prior to challenge, with one exception, in which a mouse sam- a Culture medium was collected from inoculated monolayers at 24 and 48 h postinfection and assayed for IFN-␣/␤ antiviral activity as described in the text.
b IFN units. IFN-␣/␤ antiviral activity titers (units/ml) were standardized to an international mouse IFN-␣/␤ standard preparation as described in the text.
c ND, not determined. pled 3 days postvaccination had recoverable CFU in liver and spleen samples. We continued to screen for the genetically marked vaccine strain postchallenge in all vaccinated mice. It was never detected in any target organ. Vaccinated and sham-vaccinated (PBS-vaccinated) mice were challenged with orally virulent parental strain (F6214-1) at 22 days postvaccination. Three and 5 days later, groups were sacrificed and the protection level was quantified by determining the challenge strain CFU counts in liver, spleen, and colon content samples. There was no detectable difference in the challenge strain organ CFU counts in vaccinated mice and those of the sham-vaccinated mice at 3 days postchallenge (Fig.  5 ). This indicated that vaccination had little effect on the innate immune response. Also, there was no evidence that the vaccinating dose precluded initial colonic colonization by the challenge strain. However, the challenge strain was undetectable in the spleens of vaccinated mice sacrificed 5 days postchallenge whereas the unvaccinated group carried a splenic listerial load of ca. 10 7 CFU per organ. Although the challenge strain was detected in the livers of some vaccinated mice, the CFU counts were, on average, ca. 10,000-fold lower in these mice than the liver CFU counts of the sham-vaccinated animals. A separate group of 2 vaccinated and challenged mice was observed for an additional 13 days postchallenge for lethality (the dose would normally kill at least half of the naïve mice inoculated). No lethality was witnessed. One deleterious feature of listerial vaccines is their potential to stimulate (prime) the innate immune system. Priming causes a nonspecific hyperresponsiveness for the production of TNF and other cytokines that can cause cachexia. We measured the ability of our vaccine strain to prime the host by measuring the levels of LPS-induced serum TNF and IFN-␣/␤ in mice 3 days after an oral immunizing dose (ca. 2 ϫ 10 7 CFU) of PAS394. The TNF and IFN-␣/␤ responses represent the degree to which immunization primed the host to overproduce these LPS-induced cytokines. As anticipated, vaccination with the control parental strain produced a significant increase in LPSinduced serum TNF. However, the vaccination with phage- (Fig. 6A ). Similar effects were seen when measuring LPS-induced serum IFN-␣/␤ levels (Fig. 6B) . The ability of the mutant to elicit a potent adaptive immune response in the absence of priming suggested that its exposure to immune effector cells differed from that of the parent. We sought evidence of differences by examining the GALT that includes the PP and MLN. GALT infectivity indices following oral inoculation. Potential differences in GALT infectivity between the parent and mutant strains were examined using an infectivity index that encompassed 36 h. Both the parent and mutant strains were present in proportion to the starting inoculum in the large intestine (data not shown). Likewise, when PP samples were initially assessed, both strains were represented. However, the mutant persisted for most of the time course in PP (Fig. 7) . In contrast, the parent did not remain in the PP and appeared in the liver and spleen samples by 36 h postinoculation. The presence of the mutant in PP provides an explanation for how the robust protective immunity could be generated in the absence of liver and spleen colonization. The persistence of the mutant in PP suggested that the immunity conferred was likely to be long-lived. Additionally, using a parenteral (tail vein) infectivity assay, we found at 72 and 96 h postinoculation that the glcV mutant was not defective (compared to the parent) in the ability to infect the liver and spleen (data not shown). This suggested that the mutant was being restricted to the PP (rather than escaping to the liver and spleen and being immediately eliminated).
Comparative efficacy, persistence, and magnitude of protective immunity. In addition to the challenge done at 22 days postvaccination, a vaccination-and-challenge experiment was carried out with the challenge occurring at 52 days postvaccination. In this experiment, an F6214-1 actA mutant (PAS733) was included to provide a vaccine efficacy reference point because of the well-documented use of actA mutants as vaccine platforms (11, 27) . The glcV and actA vaccine strains and a PBS control were orally administered. Selected prechallenge vaccinees were sacrificed at 3, 5, and 10 days postinoculation (two mice at each time point) and liver, spleen, and colon contents were plated to test for the presence of the genetically marked vaccine strains. The vaccine strains were undetectable in all liver and spleen samples taken from all mice prior to challenge (or postchallenge), with two exceptions, both in mice whose livers were taken at 3 days postvaccination (no CFU were detected in the spleens). One mouse had recoverable strain PAS394, and the other had PAS733.
Vaccinated and sham (PBS)-vaccinated mice were challenged orally with the parental strain (F6214-1) at 52 days postvaccination (Fig. 8) . Three and 5 days later, groups were sacrificed and the level of protection was quantified as described for the preceding 22-day challenge experiment. As with the 22-day challenge, there was little difference between vaccinated and sham-vaccinated mice 3 days postchallenge (although a small but statistically significant reduction in the spleen challenge strain CFU count was seen in the PAS394-vaccinated mice). At 5 days postchallenge, both the PAS394-and PAS733-vaccinated mice showed significantly reduced challenge strain CFU counts in both livers and spleens. The average magnitude of listerial CFU count reduction in the livers and spleens was equivalent to that seen in the 22-daychallenged mice (Fig. 5) . Colon CFU counts were omitted from Fig. 8 to aid clarity but followed the trends shown in the 22-day challenge. Two mice from each vaccinated group were monitored for 14 days postchallenge for signs of disease. All mice appeared healthy and showed no signs of illness.
DISCUSSION
An L. monocytogenes glcV mutation precludes the binding of certain listerial phages and produces a profound attenuation characterized by the absence of detectable mutant CFU in the liver and spleen in orally inoculated mice (31) . The failure of the mutant to be detected in major organs of the reticuloendothelial system led us initially to discount its potential to stimulate a robust immune response characteristic of the parent and other live attenuated vaccine strains. However, we could find no published evidence that vital organ infection is required to produce protective immunity if the immunizing route is oral. With oral inoculation, the immune system can be stimulated at a number of points along the alimentary tract without vital organ involvement. Consequently, when our glcV mutant displayed in vitro properties consistent with those of other well-described attenuated live listerial vaccine platforms (notably, ones bearing lesions in actA), we examined its potential usefulness in this regard. We found that the glcV mutant was quite capable of provoking a robust and long-lasting protective immunity in the near absence of vital organ infectivity.
In keeping with observations in our initial description of the effects of a glcV mutation (31), we noted a level of enterocyte plaque-forming efficiency lower than that of the parent at 48 h postinoculation. However, observations made at 72 h postinoculation revealed that mutant plaques, while expanding in size at a rate lower than that of parent plaques, had indistinguishable plaque-forming efficiencies at this later time point. This finding was noteworthy because it indicated that the mutant's ability to form infectious foci did not differ from that of the parent. If the mutant was as likely as the parent to initiate an infection, then the small-plaque phenotype that it displayed in enterocyte monolayers could have been due to a slower intracellular growth rate, an impeded ability to spread from cell to cell, or a combination of both.
Growth curve results indicated that the glcV mutant was fully capable of initiating an infection and growing inside a host cell indistinguishably from the parent but plateaued earlier. The mutant's intracellular growth plateau was thus most likely due to its failure to efficiently gain access to adjacent uninfected cells, resulting in fewer but more densely infected cells. This picture was supported by light microscopic examination, which revealed a high mutant cytosolic density. Consistent with this interpretation, we found that mutant-induced IFN-␣/␤ production (on a per-bacterium level) was disproportionately lower than that induced by the parent, a finding expected if the mutant was stimulating fewer host cells. and parent are equally capable of stimulating a cell to produce IFN-␣/␤, regardless of the intracellular density achieved.) Fluorescence microscopy additionally revealed a dramatically more extensive spreading of the parental strain outward from plaque margins and illustrated the similarity of our glcV mutant to an actA mutant that we had constructed for inclusion in our vaccination studies. We note here that ActA, although absent in our actA mutant, was readily detected in the glcV mutant envelope fraction and the mutant exhibited phalloidin staining similar to that of the parent when in enterocyte culture. However, we cannot rule out the possibility that the cell surface affinity of ActA (or other cell surface proteins) is not materially affected by the glcV lesion. Further examination of the glcV mutant as a vaccine strain seemed warranted at this point in part because it is well documented that actA mutants are effective immunogens, having been tested via both the oral (27) and parenteral (11) routes in mice. The ability of the glcV mutant to safely and robustly induce long-lived protective immunity to oral challenge (parenteral challenge was not examined) was demonstrated in experiments that measured the ability of vaccination to stimulate innate and adaptive immunity. In these experiments, innate immunity was not influenced, as measured by the ability of vaccination immediately (3 days) postchallenge to contain liver and spleen CFU. This conclusion was additionally supported by the inability of the mutant to prime the host's innate immune system to respond to a heterologous antigen. The absence of priming may reflect the failure of the priming dose to reach the liver and spleen. Indeed, our infectivity index experiments revealed an increased mutant persistence in lymphoid tissue in direct contact with the intestinal lumen (PP). Contact with PP could explain the effectiveness of the vaccine in producing an adaptive response in the absence of the strain's delectability in the liver and spleen.
The longevity of the protective effect afforded by the glcV mutant was tested with a challenge at 52 days postvaccination. In this experiment, an F6214-1 actA mutant (PAS733) was employed to provide a point of comparison. The protective efficacy of the glcV mutant at 52 days was indistinguishable from that seen in the 22-day challenge. Also, the level of protection was indistinguishable from that afforded by our actA mutant control strain. The latter result may indicate that the defect in cell-to-cell spreading (rather than the precise means by which it comes about) is the key feature in making an effective L. monocytogenes vaccine platform. More tests need to be performed to establish the upper limit of protection and any challenge route-specific effects.
Most of the listerial strains currently employed as vaccine platforms show evidence of vital organ damage in vaccinees (5, 11, 24) . Safety concerns necessitate the careful monitoring of volunteers (1) . Indeed, directed attempts to reduce the liver and spleen toxicity of candidate vaccine strains are active areas of research (5, 25) . In addition, parenteral vaccination routes ensure, rather than limit, the exposure of vital organs to listeriae and bypass steps in the normal infectious process involving the alimentary tract that could stimulate protective immunity and reduce or eliminate the need for liver and spleen colonization (21) . Indeed, we saw no evidence of a reduction in the glcV mutant's ability to establish an initial infection of the liver and spleen compared with that of the parent strain when both were delivered parenterally. This is the first report that describes the practical (oral) delivery of an attenuated mutant that produces protective immunity in the near absence of vital organ infectivity. Also, we employed a parental L. monocytogenes strain that is particularly virulent when administered orally to mice (12) . The use of this strain in combination with the A/J mouse line (10) provides a strong test of the attenuating power of the glcV lesion. Other listerial strains (including those of the well-described EGD lineage [22] ) appear to be naturally attenuated in mice when administered via the oral route (19, 34) , rendering the important issue of safety difficult to define using the mouse as a model host and employing the natural infection route (17) . This problem is well illustrated by our results when we introduced an actA mutation into our parental strain as a benchmark control in our immunization experiments. The lesion rendered our parental strain as safe and effective as our glcV mutant. In contrast, in the EGD lineage, oral inoculation with an actA mutant elicits substantial liver and spleen infectivity in mice (27) . This result is likely reflective of the ca. 500-fold larger dose required for this strain to be orally infective (27) . Whereas problems associated with the low oral infectivity of the EGD lineage strains have been partially overcome by various means (19, 34) , other strains (2, 9, 26), including ours (12) have a naturally high oral infectivity in mice, perhaps due to additional or alternative ways of interacting with host cells (17, 18, 23) .
Several medically important microorganisms are attenuated by mutations conferring phage resistance, specifically by mutations that eliminate phage binding (8, 29, 31) . Most recently, investigators employing Staphylococcus aureus successfully employed an attenuated phage-resistant mutant as a live vaccine strain (7) . As reinforced here, the authors suggest that phage resistance may be generally employed as a tool to aid in live vaccine discovery and development.
